Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ZAI Builds On Sanofi Ties For Lung Cancer Candidate

This article was originally published in PharmAsia News

Executive Summary

China’s ZAI Lab has in-licensed its third preclinical drug candidate from Sanofi, a novel multi-kinase inhibitor aimed at a non-small cell lung cancer target and other oncology indications. The new agreement indicates ZAI’s R&D strategy of bringing in novel early stage assets with large unmet needs in China and globally.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts